3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Prostatic Neoplasms
3
Breast Neoplasms
3
Ovarian Neoplasms
2
Triple Negative Breast Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neurologic Manifestations
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Lymphoma, Follicular
1
Leukemia, Myeloid, Acute
1
Kidney Neoplasms
1
Graft vs Host Disease
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
COVID-19
1
Brain Neoplasms
1
Interventions
Interferon-alpha
7
aldesleukin
6
Sunitinib
6
Radiotherapy
5
Nivolumab
5
Doxorubicin
5
Vincristine
4
Ipilimumab
4
Filgrastim
4
Dactinomycin
4
Chemotherapy, Adjuvant
4
Axitinib
4
cabozantinib
3
Sorafenib
3
Everolimus
3
Etoposide
3
Cyclophosphamide
3
temsirolimus
2
pembrolizumab
2
Ifosfamide
2
G250 monoclonal antibody
2
Fluorouracil
2
Carboplatin
2
Bevacizumab
2
vitespin
1
shark cartilage extract
1
pazopanib
1
lenvatinib
1
glutamic acid diethyl ester
1
cemiplimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Kidney Neoplasms
×
Atorvastatin
×
Clear all
NCT05796973
2025-06-27
MOVES
Tampere University Hospital
Phase 3
Recruiting
240 enrolled